secwatch.observer — SEC 8-K summary
======================================

Issuer:     SEELOS THERAPEUTICS, INC. (—)
CIK:        0001017491
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040106
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seelos increases convertible note principal by $1.49M to $13.44M, secures forbearance
--------------------------------------------------------------------------------

- Principal increased by $1,492,844 to $13,435,599 effective March 27, 2024.
- Holder Lind Global will forbear from asserting Material Adverse Effect based on pre-Sept 30, 2023 events until April 29, 2024.
- Company must seek stockholder approval by July 31, 2024 before issuing shares on conversion of the increase.
- Minimum cash balance of 50% of outstanding principal resumes after April 29, 2024; waived until then.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1017491/000110465924040106/0001104659-24-040106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1017491/000110465924040106/tm249064d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer